Keywords: داکلاتاشیر; Direct-acting antivirals; Daclatasvir; Ledipasvir; Native fluorescence; Real human plasma; Pharmaceutical formulations;
مقالات ISI داکلاتاشیر (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: داکلاتاشیر; asunaprevir; budget impact; cost-effectiveness; daclatasvir; hepatitis C virus;
Keywords: داکلاتاشیر; DAA; NS3/4A Protease Inhibitor; Nucleoside/Nucleotide; Non-nucleoside; DAA; direct-acting antiviral agent; DCV; daclatasvir; HCV; hepatitis C virus; HTA; host-targeted antiviral agent; IFN; interferon; ISG; interferon-stimulated gene; NI; nucleoside inhib
Keywords: داکلاتاشیر; Crystal forces; Atropisomer; Intrinsic supersaturation; Energy barrier; Crystallization tendency; Daclatasvir
Keywords: داکلاتاشیر; Asunaprevir; Chronic hepatitis C; Daclatasvir; Direct acting antiviral agents; Drug-induced lung injury
Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: Application to human plasma and stability study
Keywords: داکلاتاشیر; Daclatasvir; Micellar enhancement; Spectrofluorimetric; Stability study; Biological fluids;
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major
Keywords: داکلاتاشیر; DAA; Direct Acting Antiviral; DCV; Daclatasvir; ETR; End of Treatment Response; HCV; Hepatitis C Virus; PegINF-α; Pegylated Interferon-α; RBV; Ribavirin; RVR; Rapid Virological Response; SOF; Sofosbuvir; SVR12; Sustained Virological Response Post-treatm
Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice
Keywords: داکلاتاشیر; HCV; Glecaprevir; Pibrentasvir; Sofosbuvir; NS5A inhibitor resistance associated variant; P32 deletion; Human hepatocyte chimeric mouse; ASV; asunaprevir; DAAs; Direct-acting antivirals; DCV; daclatasvir; GLE; glecaprevir; HCV; hepatitis C virus; LDV; led
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: داکلاتاشیر; Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Keywords: داکلاتاشیر; Sofosbuvir; Daclatasvir; Simeprevir; DAA; Sustained virological response;
Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis
Keywords: داکلاتاشیر; DAA; Direct Acting Anti-viral; FIB 4; Fibrosis Score 4; HCV; Hepatitis C Virus; IL-18; Interleukin 18; INF; Interferon; NS; Non-Structural; PCR; Polymerase Chain Reaction; RFLP; Restriction Fragment Length Polymorphism; RNA; Ribonucleic Acid; SNPs; Single
Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis
Keywords: داکلاتاشیر; Sofosbuvir; Daclatasvir; HPTLC-dual wavelength spectrodensitometry; Simultaneous determination; Real human plasma; Pharmaceutical formulations;
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients
Keywords: داکلاتاشیر; UPLC-MS/MS; ultra performance liquid chromatograpy; LOD; limit of detection; LOQ; limit of quantification; HCV; hepatitis C virus; NS5A/5B; non-structural 5A/5B; SVR; sustained virological response; Sofosbuvir; GS-331007; Daclatasvir; DAA; HCV; Therapeu
Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India
Keywords: داکلاتاشیر; DAA; Direct Acting Antiviral; DCV; Daclatasvir; EASL; European Association of Study of the Liver (EASL); ETR; End of Treatment Response; HBV; Hepatitis B; HCC; Hepatocellular Carcinoma; HCV; Hepatitis C Virus; HIV; Human Immunedeficiency Virus; ITT; inten
Probing DNA damage induced by common antiviral agents using multiple analytical techniques
Keywords: داکلاتاشیر; Antiviral agents; Anticancer agents; Hepatocellular carcinoma; DNA damage; Ledipasvir; Daclatasvir; EvaGreen; Absorption spectroscopy; MALDI-TOF mass spectrometry; Fluorescence spectroscopy;
Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study
Keywords: داکلاتاشیر; HPLC-UV; Human urine; Human plasma; Dissolution test; Sofosbuvir; Daclatasvir;
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Keywords: داکلاتاشیر; HCV; RASs; DAA; Virologic Treatment Failure; DAA; direct-acting antiviral; DCV; daclatasvir; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; NS; nonstructural protein; PCR; polymerase chain reaction; PEG IFN; pegylated interf
Consenso Mexicano para el Tratamiento de la Hepatitis C
Keywords: داکلاتاشیر; Consenso; Agentes antivirales de acción directa; RegÃmenes libres de interferón; Ribavirina; Consensus; Direct-acting antiviral agents; Interferon-free regimens; Ribavirin; AAD; antivirales de acción directa; AASLD; Asociación Americana para el Estud
The Mexican consensus on the treatment of hepatitis C
Keywords: داکلاتاشیر; Consensus; Direct-acting antiviral agents; Interferon-free regimens; Ribavirin; Consenso; Agentes antivirales de acción directa; RegÃmenes libres de interferón; Ribavirina; AASLD; American Association for the Study of Liver Diseases; AFP; alpha-fetopro
Nano-magnetite/ionic liquid crystal modifiers of carbon nanotubes composite electrode for ultrasensitive determination of a new anti-hepatitis C drug in human serum
Keywords: داکلاتاشیر; MWCNTs; Ionic liquid crystal; Magnetite iron oxide; Daclatasvir; Anti-hepatitis C drugs; Human serum; Antiviral drugs;
Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
Keywords: داکلاتاشیر; DAA; daclatasvir; HCV; hemodialysis; India; sofosbuvir;
Response Tailored Protocol Versus the Fixed 12Â Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
Keywords: داکلاتاشیر; Chronic hepatitis C infection; Sofosbuvir; Daclatasvir; Response tailored therapy; Very rapid virologic response; SVR12;
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
Keywords: داکلاتاشیر; Chronic hepatitis C; DAA treatment; Immune response; miRNA-122; HCV; hepatitis C virus; IP-10; interferon gamma-induced protein; CHC; chronic hepatitis C; DAAs; direct acting antivirals; SVR; sustained virological response; miR-122; microRNA-122; RAS; res
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients
Keywords: داکلاتاشیر; Chronic hepatitis C; Treatment; Sofosbuvir; Daclatasvir; Direct antiviral agents; Cirrhosis; Severe fibrosis; Genotype 1; Hepather cohort;
Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?
Keywords: داکلاتاشیر; ALT; alanine aminotransferase; CHC; chronic hepatitis C; CI; confidence interval; DAAs; direct-acting antiviral agents; DCV; daclatasvir; EASL; The European Association for the Study of the Liver; GT; Genotype; HCC; hepatocellular carcinoma; HCV; hepatiti
Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir
Keywords: داکلاتاشیر; HPLC; Diode array detection; Daclatasvir; HCV; Stability-indicating assay; Forced degradation; CLHP; Détection barette de diode; Daclatasvir; HCV; Methode indicatrice de stabilité; Dégradation forcée;
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective
Keywords: داکلاتاشیر; cost-effectiveness; daclatasvir; Egypt; hepatitis C virus; ledipasvir; sofosbuvir;
Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
Keywords: داکلاتاشیر; CTP; Child-Turcotte-Pugh staging; CSA; cyclosporine A; DAA; directly acting antivirals; DCV; daclatasvir; DDLT; deceased donor liver transplant; DSB; dasabuvir; EBV; elbasvir; FCH; fibrosing cholestatic hepatitis; GT; genotype; GRZ; grazoprevir; HCV;
Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma
Keywords: داکلاتاشیر; Daclatasvir; BMS-790052; HCV NS5A inhibitor; Solid-phase extraction; HPLC-UV; Therapeutic drug monitoring;
Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites
Keywords: داکلاتاشیر; Chronic Hepatitis C; Direct-Acting Antiviral Agent; DAA; CHX; cycloheximide; DCV; daclatasvir; DI; domain I; DMV; double membrane vesicle; ER; endoplasmic reticulum; HCV; hepatitis C virus; LD; lipid droplet; MOI; multiplicity of infection; NS; non-struct
Finally, safe and effective treatment options for hepatitis C in hemodialysis patients
Keywords: داکلاتاشیر; HCV; hepatitis C virus; ESRD; end-stage renal disease; HD; hemodialysis; DAA; direct acting antivirals, SOF, sofosbuvir; SIM; simeprevir; LED; ledipasvir; DCV; daclatasvir; RBV; ribavirn; IFN; interferon; SVR; sustained virologic response; pk; pharmacokin
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Keywords: داکلاتاشیر; HCV; hepatitis C virus; DAA; direct-acting antiviral; MELD; model for end-stage liver disease; SVR; sustained virological response; EAP; expanded access programme; HCVRUK; hepatitis C Research UK; SOF; sofosbuvir; LDV; ledipasvir; DCV; daclatasvir; RBV; r
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
Keywords: داکلاتاشیر; AE; adverse events; DAAs; direct-acting antiviral agents; DCV; daclatasvir; EOT; end of treatment; GFR; glomerular filtration rate; HCV; hepatitis C virus; HIV; human immunodeficiency virus; IMS; immunosuppressive; LLOQ; lower limit of quantification; LT;
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
Keywords: داکلاتاشیر; daclatasvir; hepatitis C; HIV; matching-adjusted indirect comparison; sofosbuvir; ribavirin;
Research ArticleDaclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Keywords: داکلاتاشیر; HCV; hepatitis C virus; SMV; simeprevir; PegIFN; peginterferon; RBV; ribavirin; DCV; daclatasvir; ASV; asuneprevir; SVR; sustained virologic response; LLOQ; lower limit of quantitation; AE; adverse event; SVR12; sustained virologic response at posttreatme
Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study
Keywords: داکلاتاشیر; Daclatasvir; UPLC-MS/MS; Plasma; Validation; Pharmacokinetics; Bioequivalence;
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Keywords: داکلاتاشیر; HCV; hepatitis C virus; DAA; direct-acting antivirals; SVR; sustained virological response; MELD; model for end-stage liver disease; HCC; hepatocellular carcinoma; BCLC; Barcelona Clinic Liver Cancer group; LOD; limit of detection; EOT; end of treatment;
Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication
Keywords: داکلاتاشیر; Hepatitis C virus; NS5A; Prodrug; Daclatasvir; Pharmacokinetics;
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBVÂ +Â daclatasvir: A case study using ultra deep pyrosequencing
Keywords: داکلاتاشیر; Hepatitis C virus; Genotype 4; NS5A; UDPS; Daclatasvir;
Review ArticleInterferon-free therapy for hepatitis C: The hurdles amid a golden era
Keywords: داکلاتاشیر; Daclatasvir; Hepatitis C; Interferon; Simeprevir; Sofosbuvir;
Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015
Keywords: داکلاتاشیر; SOF; Sofosbuvir; DCV; Daclatasvir; RBV; Ribavirin; CP; Child-Pugh; SVR; Sustained virologial response; HVPG; Hepatic venous pressure gradient; G; Genotype; LDV; Ledipasvir; GZR; grazoprevir; EBR; Elbasvir; SMV; Simeprevir; CKD; Chronic kidney disease; RAV
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function
Keywords: داکلاتاشیر; Immune Regulation; NS5A Inhibitor; NS3 Inhibitor; ISG; APC; allophycocyanin; ASV; asunaprevir; CXCL; chemokine C-X-C motif ligand; DAA; direct-acting antiviral; DCV; daclatasvir; EMA; ethidium monoazide; EOT; end of treatment; FBS; fetal bovine serum; FIT
Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma
Keywords: داکلاتاشیر; LC-MS/MS; Daclatasvir; Asunaprevir; Beclabuvir (BMS-791325) and its metabolite; Human plasma; Pharmacokinetics;
Liver, Pancreas and Biliary TractSofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
Keywords: داکلاتاشیر; Cholestatic hepatitis; Cirrhosis; Daclatasvir; Direct antiviral agents; Disease recurrence; HCV; MELD; Sofosbuvir;
Review ArticleSofosbuvir as backbone of interferon free treatments
Keywords: داکلاتاشیر; DAAs; Daclatasvir; HCV; IFN-free; NS5B nucleotide inhibitors; Ribavirin; Simeprevir; Sofosbuvir;
Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b
Keywords: داکلاتاشیر; asunaprevir; clinical effectiveness; daclatasvir; hepatitis C;
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Keywords: داکلاتاشیر; Direct-Acting Antivirals; Interferon-Free Regimens; Sofosbuvir; Simeprevir; Daclatasvir; DAA; direct-acting antiviral; HCV; hepatitis C virus; HIV; human immunodeficiency virus; HTA; host-targeted agent; IFN; interferon; RdRp; RNA-dependent RNA polymera
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
Keywords: داکلاتاشیر; Antiviral Agent; Replication; Therapy; RNA-Dependent RNA Polymerase; BOC; boceprevir; CI; confidence interval; DAA; direct-acting antiviral; DCV; daclatasvir; EC50; 50% effective concentration; FFU; focus-forming unit; GLuc; Gaussia princeps luciferase; H
HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives
Keywords: داکلاتاشیر; Daclatasvir; HCV; NS5A; Mandelamide X-ray; Pan-genotype HCV replicon inhibition; Phenylglycine;
A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir
Keywords: داکلاتاشیر; HCV resistance barrier; Luciferase assay; Daclatasvir; BMS-790052; DAA;